Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineHighmark Pennsylvania Modafinil Prior Auth Policy …
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Prior Authorization Criteria — Modafinil (Provigil) for Sleep Disorders

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization requirements for Provigil (modafinil) and generic modafinil for members of Highmark Pennsylvania when used to treat sleep-related disorders (e.g., obstructive sleep apnea, narcolepsy, idiopathic hypersomnia, shift-work sleep disorder, MS-related fatigue). It affects prescribing providers who must submit clinical information to obtain authorization.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyPrior Authorization Criteria — Modafinil (Provigil) for Sleep Disorders
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical documentation, medication details, and supporting objective sleep data.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Indication sections

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥14dActigraphy duration
    ≥660m24-hr sleep threshold
    ESS, MWT, MSLTObjective tests requested

    Coverage Criteria for Modafinil (Provigil)

    Indication-specific coverage criteria

    Covered when ALL of the following supporting documentation is provided for the specific indication

    General documentation: Completed prior authorization form with member and provider information, requested drug (Provigil or generic modafinil), dose, quantity/day supply, and diagnosis (ICD-10) codes; submitted via fax or mail per form instructions.

    See form completion and submission instructions.

    Medication history / Step therapy: Documentation of prior therapeutic failure, intolerance, or contraindication to a generic central nervous system (CNS) stimulant (for example, dextroamphetamine or methylphenidate) when applicable; if requesting more than one 200 mg tablet per day, documentation that 200 mg once daily was inadequate.

    Provide prior medication history as requested on the form.

    Obstructive sleep apnea specific: Documentation of current receipt and compliance with positive airway pressure (PAP) therapy or documentation of intolerance to PAP, or current use and compliance with a custom titratable oral appliance; include diagnostic polysomnography data (AHI and/or RDI) and relevant symptom checklist items.

    Include PSG AHI/RDI and PAP/oral appliance use per form.

    Narcolepsy specific: Baseline Epworth Sleepiness Scale (ESS) and Maintenance of Wakefulness Test (MWT) scores; multiple sleep latency test (MSLT) results including mean sleep latency and number of SOREMPs; PSG-reported SOREMPs if available; and cerebrospinal fluid hypocretin-1 level if hypocretin deficiency is suspected.

    Provide ESS, MWT, MSLT, PSG, and CSF hypocretin-1 data as applicable.

    Idiopathic hypersomnia specific: Baseline ESS and MWT; MSLT results; documentation of presence or absence of cataplexy; and objective documentation of total 24-hour sleep time ≥660 minutes either by polysomnography or by wrist actigraphy averaged across ≥7 days of monitoring.>=660 minutes

    PSG or actigraphy demonstrating >=660 minutes (11 hours) total sleep time per 24 hours averaged per monitoring requirements.

    Shift-work sleep disorder specific: Symptoms temporally associated with a recurring work schedule that overlaps usual sleep time, accompanied by reduction in total sleep time, symptoms present for ≥3 months, and sleep log or actigraphy monitoring for at least 14 days including both work and free days; exclude sleep disturbance due to another sleep, medical/neurological, mental, medication-related, or substance use disorder.>=3 months; >=14 days monitoring

    Provide 14-day sleep log or actigraphy including work and free days and documentation excluding other causes.

    Multiple sclerosis related fatigue: Documentation that the member has significant fatigue related to multiple sclerosis and that modafinil is being considered for treatment of this fatigue.

    Indicate presence of significant MS-related fatigue on the form.

    Reauthorization criteria

    Covered for reauthorization when ALL of the following are met

    Current therapy: Member is currently receiving the requested medication and the request is for continuation or reauthorization.

    Confirm current therapy status on the reauthorization section of the form.

    Clinical benefit demonstrated: Documentation that the member's symptoms (for example, fatigue or daytime sleepiness) have improved while on therapy.

    Provide clinical notes or symptom assessments indicating improvement.

    Objective improvement: Documentation of decreased daytime sleepiness demonstrated by improvement on the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) compared to baseline.

    Provide comparative ESS or MWT results as recorded on the reauthorization portion of the form.

    For a diagnosis of shift-work sleep disorder, the form requires exclusion of other causes of sleep disturbance. Specifically, the provider must confirm that the member’s sleep disturbance is not explained by another current sleep disorder, a medical or neurological disorder, a mental disorder, medication use, or a substance use disorder. This exclusion is necessary to ensure that symptoms are attributable to the work schedule and to support medical necessity for modafinil in this indication.

    Completion of the prior authorization form documents a provider’s request for coverage but does not ensure payment. Authorization does not guarantee payment; coverage and payment remain subject to the member’s eligibility and benefits at the time the claim is submitted. Providers must submit a complete, legible form with required clinical documentation and accurate member information via the fax or mailing instructions on the form to initiate review.

    Requested Medication and Diagnostic Codes

    Requested medicationmixed
    Provigil / ModafinilRequested drug — Brand Provigil or Generic Modafinil, strengths 100mg or 200mg
    Diagnosis codes (provider-entered)ICD-10
    ICD-10Diagnosis and/or ICD-10 code(s) (provider to supply)
    inv-07: 24-hour total sleep time (idiopathic hypersomnia) — threshold value
    24-hour total sleep time threshold>= 660 minutes (11 hours) per 24 hours
    Acceptable measurement methodsPolysomnography (PSG) or wrist actigraphy
    Averaging requirement (actigraphy)≥ 7 days of monitoring for actigraphy when used to support the threshold
    inv-08: Actigraphy/sleep log duration (shift-work sleep disorder) — required monitoring period
    Required monitoring period>= 14 days including both work and free days
    Purpose of monitoringDocument reduction in total sleep time and temporal association with recurring work schedule

    What the Prescribing Provider Must Submit

    Prior Authorization

    Prior authorization required — submit form with clinical documentation

    Prior authorization is required. Submit the completed prior authorization form with all required clinical documentation and medication details; fax to 1-866-240-8123 or mail to 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222 per the form instructions.

    Step Therapy

    Step therapy / quantity justification — document prior stimulant failure or inadequate control

    Document therapeutic failure, intolerance, or contraindication to a generic CNS stimulant (for example dextroamphetamine or methylphenidate) when applicable; if requesting more than one 200 mg tablet per day, indicate whether daytime sleepiness was inadequately controlled on Provigil (Modafinil) 200 mg once daily.

    Background

    Modafinil (Provigil or generic modafinil) is used to treat excessive daytime sleepiness across several clinical contexts. Common indications include sleepiness associated with obstructive sleep apnea, narcolepsy, idiopathic hypersomnia, shift-work sleep disorder, and fatigue related to multiple sclerosis. The prior authorization form is structured to collect objective sleep study data, symptom scales, and medication history to document diagnosis, baseline severity, and treatment response when modafinil is requested.

    Key Definitions

    inv-16: SOREMP — Sleep-onset rapid eye movement period; requested from MSLT and PSG for narcolepsy evaluation
    DefinitionSleep-onset rapid eye movement period (SOREMP): REM occurring at sleep onset; number of SOREMPs requested from MSLT and PSG for narcolepsy evaluation
    MSLT data requestedNumber of SOREMPs and mean sleep latency from the MSLT
    PSG data requestedNumber of SOREMPs on diagnostic polysomnography may also be provided
    inv-17: 24-hour total sleep time threshold for idiopathic hypersomnia — polysomnography or actigraphy showing total sleep time ≥660 minutes averaged over monitoring period
    Diagnostic thresholdPolysomnography or actigraphy showing total sleep time >= 660 minutes (11 hours) per 24 hours
    Actigraphy averaging
    Policy Summary
    PayerHighmark Pennsylvania
    PolicyPrior Authorization Criteria — Modafinil (Provigil) for Sleep Disorders
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required clinical documentation, medication details, and supporting objective sleep data.
    SourceLink
    On This Page
    Coverage Criteria for Modafinil (Provigil)Requested Medication and Diagnostic CodesWhat the Prescribing Provider Must SubmitBackgroundKey Definitions
    Symptom duration requirement>= 3 months of symptoms in addition to monitoring
    Documentation Required

    Submit completed, legible PA form with member/provider and medication details

    Submit a completed, legible prior authorization form that includes member and provider information, the requested drug (brand Provigil or generic modafinil), strength, dose, quantity/day supply, and diagnosis with ICD-10 code(s).

    Documentation Required

    Include indication-specific objective data (ESS, MWT, MSLT, PSG/actigraphy)

    Include indication‑specific objective data with the request: for narcolepsy and idiopathic hypersomnia provide baseline ESS and MWT and MSLT results (mean sleep latency and number of SOREMPs); include PSG SOREMPs or CSF hypocretin-1 when applicable; for idiopathic hypersomnia provide 24‑hour total sleep time data (≥660 minutes) from PSG or actigraphy.

    Documentation Required

    Provide prior medication history showing failure/intolerance to generic stimulants

    Provide prior medication history documenting therapeutic failure, intolerance, or contraindication to a generic CNS stimulant; list other medications the member has tried and failed.

    Denial Risk

    Authorization does not guarantee payment — check member eligibility

    Payment is subject to member eligibility; authorization does not guarantee payment.

    Actigraphy must demonstrate >= 660 minutes per 24 hours averaged across >= 7 days of monitoring
    Alternate methodA single 24-hour PSG demonstrating >= 660 minutes total sleep time is acceptable